BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors - Seite 3
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal
securities laws, including statements regarding BeiGene’s plans, strategies, commitments, aspirations, and goals for the Talk About It program, and BeiGene’s plans, commitments, aspirations and
goals under the caption “About BeiGene”. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's
ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of
regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed medicines and
drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene's reliance on third parties to conduct drug
development, manufacturing, commercialization, and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to
obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; the impact of the COVID-19 pandemic on BeiGene’s clinical
development, regulatory, commercial, manufacturing, and other operations, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly
report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All
information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.
1 Cancer Support Community (2022). Cancer Experience Registry Spotlight Survey: Identifying Barriers to Accessing Mental Health Care among Cancer Patients and Survivors [Unpublished data, August 2021]
Lesen Sie auch
View source version on businesswire.com: https://www.businesswire.com/news/home/20221209005054/en/
The BeiGene Stock at the time of publication of the news with a raise of +3,78 % to 192USD on Tradegate stock exchange (02. Dezember 2022, 22:26 Uhr).